⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RPRX News
Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
globenewswire.com
RPRX
CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer
businesswire.com
RPRX
ABBV
NVS
ZURA
INCY
AZN
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
globenewswire.com
RPRX
NUVL
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
prnewswire.com
ONCY
IMRX
TNGX
MRNA
RPRX
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
globenewswire.com
RPRX
DNLI
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
globenewswire.com
DNLI
RPRX
Royalty Pharma to Present at Upcoming Investor Conferences
globenewswire.com
RPRX
Royalty Pharma Reports Third Quarter 2025 Results
globenewswire.com
RPRX
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
globenewswire.com
RPRX
Royalty Pharma Declares Fourth Quarter 2025 Dividend
globenewswire.com
RPRX